This HTML5 document contains 120 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/
n11http://dx.doi.org/10.2147/

Statements

Subject Item
wd:Q37601293
rdf:type
wikibase:Item
schema:description
научни чланак videnskabelig artikel vedecký článok vetenskaplig artikel scientific article published on 19 February 2014 article scientifique artículu científicu espublizáu en 2014 wetenschappelijk artikel articolo scientifico наукова стаття, опублікована в лютому 2014 vědecký článek article científic artigo científico مقالة علمية نشرت في 19 فبراير 2014 bilimsel makale wissenschaftlicher Artikel
p:P577
wds:Q37601293-2BEE1A41-F9FA-4BF7-ADDF-54FDE75F97DD
wdt:P577
2014-02-19T00:00:00Z
p:P407
wds:Q37601293-2363F4BA-C429-4717-A6AB-F693B9ADA748
wdt:P407
wd:Q1860
p:P2860
wds:Q37601293-F3A5B470-70CB-4415-A5B9-C39D1955EB35 wds:Q37601293-FC20798B-E72A-45B6-98E1-730746E4B0CE wds:Q37601293-FEE61967-3729-4FDE-BE78-367226245276 wds:Q37601293-925F3B70-219B-4E90-9B17-A5CEC9C70F03 wds:Q37601293-970332DE-3C80-4D2C-8D87-A8722102D44D wds:Q37601293-99185BCD-BF8A-4950-90A2-F40892FE8E03 wds:Q37601293-9C9F1C60-A002-4A58-A431-67E4DAC73BE3 wds:Q37601293-BAE2FB3D-1CFD-4AB0-93C0-0214D0AE5014 wds:Q37601293-C1B35D80-3FA7-4516-BCF9-ABF29DA4E472 wds:Q37601293-CF55B19F-EC62-4383-AA5B-E5B5789D9FF8 wds:Q37601293-D7ED6B47-72EC-4A19-99D3-61281F0451CA wds:Q37601293-507F1C69-0D66-4BCC-813F-CB8FFDD4EBD7 wds:Q37601293-52676084-F964-4B5F-A0BB-35CBFE84E50E wds:Q37601293-62FCAA2C-94A7-44BC-BC95-77D4A72BE738 wds:Q37601293-67620DFF-4B74-4EE2-A283-6AF53892DF43 wds:Q37601293-6C86F34F-55AA-4EE6-94ED-55BBCD264301 wds:Q37601293-75C73F7D-6538-4085-9272-AC976F6FF748 wds:Q37601293-778D0B36-A59C-49BC-8849-65DFD94F3C77 wds:Q37601293-042A3C58-6803-4932-AAAC-EC68D8BB6514 wds:Q37601293-0BBB9294-DA66-4AC4-BC92-A872EE7C58B0 wds:Q37601293-0F96CF92-E4A7-4129-905E-781C4D965AC2 wds:Q37601293-141754AC-B0FC-4B9E-BC10-C1BAB2B867ED wds:Q37601293-15053B00-881E-41FD-84E2-3CE65028A3A1 wds:Q37601293-164054DA-82BF-481C-87D1-70E22C888EFA
wdt:P2860
wd:Q53163538 wd:Q56900240 wd:Q37565259 wd:Q34395229 wd:Q86114165 wd:Q38012057 wd:Q24618690 wd:Q37977920 wd:Q38166382 wd:Q36527247 wd:Q24679736 wd:Q27861062 wd:Q46572104 wd:Q51738566 wd:Q36283747 wd:Q85031597 wd:Q34614776 wd:Q40298916 wd:Q37809158 wd:Q28485085 wd:Q34657638 wd:Q37809150 wd:Q58024768 wd:Q37810319
p:P2093
wds:Q37601293-0CBC1D57-85E2-44C0-B5A7-510439534B63 wds:Q37601293-301AB007-D214-4C67-928F-35378B7FC386 wds:Q37601293-843BD9C8-604C-4AF8-90B4-E77BFB0193F7 wds:Q37601293-C25761E5-4354-42BF-A6C2-53BD0A5B3DED
wdt:P2093
Giuseppina Della Vittoria Scarpati Chiara Carlomagno Stefano Pepe Celeste Fusciello
rdfs:label
Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Ipilimumab in the treatment of metastatic melanoma: management of adverse events.
skos:prefLabel
Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Ipilimumab in the treatment of metastatic melanoma: management of adverse events.
schema:name
Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Ipilimumab in the treatment of metastatic melanoma: management of adverse events.
p:P50
wds:Q37601293-343A4E72-4F3B-4510-858A-937535ADAC3E wds:Q37601293-E3837DA0-878B-4914-942A-EBE37D6BC5F8 wds:Q37601293-9BD90B4A-01C1-4601-8A71-E831A1CC9D80
wdt:P50
wd:Q63869450 wd:Q42325106 wd:Q90626068
p:P1476
wds:Q37601293-A7B850B2-68AB-4CF1-9313-207B6A36C0BD
wdt:P1476
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
p:P304
wds:Q37601293-8ADD4F57-E2EA-4B41-A4A2-39DCEBDD0E53
wdt:P304
203-209
p:P31
wds:Q37601293-45057BD7-ED3A-4AB0-8688-09CC07BA4E9F wds:Q37601293-98c63031-9103-4889-b0cd-96758524f9d6
wdt:P31
wd:Q7318358 wd:Q13442814
p:P921
wds:Q37601293-1A2384E2-7C7C-4052-BC3B-27CF1106CB56 wds:Q37601293-E02F0359-498F-4A2D-8365-2689BC2C52FF
wdt:P921
wd:Q2459042 wd:Q18975855
p:P698
wds:Q37601293-15B075F5-D3AB-4E84-98CE-C26278601B75
wdtn:P698
n12:24570590
wdt:P698
24570590
p:P1433
wds:Q37601293-4F0F08BA-8EF4-42B1-BDFA-720C9F467C72
wdt:P1433
wd:Q7092081
p:P478
wds:Q37601293-C72EADB3-5192-4B2F-BBD5-AE62518CD436
wdt:P478
7
p:P356
wds:Q37601293-8A5EA14B-A5F6-4B14-A490-0F1A8EB7493B
wdtn:P356
n11:OTT.S57335
wdt:P356
10.2147/OTT.S57335
p:P275
wds:Q37601293-10f1f6ff-dbe2-44c5-b778-9e6d6f0a2fe3
p:P6216
wds:Q37601293-28abbbd4-d227-4a62-956f-93053d0d5851
wdt:P275
wd:Q18810331
wdt:P6216
wd:Q50423863
p:P932
wds:Q37601293-66169F53-071E-4725-8DEA-03D4B7CE509D
wdt:P932
3933725